

October 24, 2026

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers, Dalal
Street Fort, Mumbai- 400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Subject: Announcement under Regulation 30 regarding the licensing and supply agreement with Laboratorio Libra S.A. ("Libra")

Dear Sir/Madam,

In accordance to Regulation 30 read with Part A of Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform that the Company has entered into a licensing and supply agreement with Libra. Press Release dated October 24, 2026 titled as "**Orchid Pharma Expands Exblifep® (Cefepime/Enmetazobactam) into Latin America through Licensing and Supply Agreement with Libra**" is enclosed herewith.

You are requested to take the above information on record.

Thanking You,

For **Orchid Pharma Limited**

KAPIL

DAYYA

Digitally signed by
KAPIL DAYYA
Date: 2026.10.24
16:47:25 +05'30'

Kapil Dayya

Company Secretary & Compliance Officer

Membership No.: F10698

Encl: As Above

Registered Office:

Orchid Pharma Limited
Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate,
Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India.

Corporate Office:

15th Floor, Tower 1, DLF Corporate Greens, Sector 74A,
Gurugram - 122004, Haryana, India

24th October, 2026

Orchid Pharma Expands Exblifep® (Cefepime/Enmetazobactam) into Latin America through Licensing and Supply Agreement with Libra

Orchid Pharma Ltd. (Orchid) and Libra (Libra) have signed a licensing and supply agreement covering Exblifep® (cefepime/enmetazobactam) across nine Latin American markets. Exblifep is a novel antibiotic combination indicated for complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gram-negative pathogens. Commercialization in each market is subject to approval by the relevant national regulatory authority.

Designed as a carbapenem-sparing option, Exblifep targets serious hospital infections driven by ESBL-producing Gram-negative bacteria. It holds approvals from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), features in the IDSA and EUCAST treatment guidelines, and is the first new chemical entity invented by an Indian pharmaceutical company to secure both approvals.

Libra receives exclusive rights to register, import, and market Exblifep in Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Panama, Paraguay, and Uruguay, while Orchid manufactures and supplies the finished dosage form. **Over the first 10 years, the partnership is expected to represent a potential commercial opportunity of approximately USD 80 million, based on projected demand across these markets.**

"Extending Exblifep into Latin America is a priority for Orchid, and Libra is well placed to lead its introduction across these markets. Together, we aim to give clinicians in the region a new option for treating serious Gram-negative hospital infections." - **Manish Dhanuka, Managing Director, Orchid Pharma Ltd.**

"We are honoured to partner with Orchid Pharma to bring Exblifep to Latin America, expanding access to an innovative therapeutic option for patients across the region while contributing to the response to the growing challenge of antimicrobial resistance." - Carlos Scherschener, CEO, Laboratorio Libra S.A.

About Orchid Pharma Limited

Orchid Pharma Limited is a fully vertically integrated pharmaceutical company with end-to-end capabilities from Key Starting Materials (KSMs) to Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs), focused on complex injectable antibiotics. Orchid is the first Indian pharmaceutical company to invent a New Chemical Entity (NCE) approved in both the United States and Europe, with the product commercially marketed in Europe and India. The company operates globally approved manufacturing facilities compliant with USFDA and EU-GMP standards. www.orchidpharma.com

Registered Office:

Orchid Pharma Limited
Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate,
Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India.

Corporate Office:

15th Floor, Tower 1, DLF Corporate Greens, Sector 74A,
Gurugram - 122004, Haryana, India

About Libra

Founded in Uruguay in 1961, Laboratorio Libra is a Latin American pharmaceutical company focused on providing access to innovative treatments in specialized therapeutic areas, including infectology, critical care, oncology, nutrition, HIV and rare diseases. Libra manufactures and commercializes its own products and represents leading international pharmaceutical companies. Through its offices and commercial network, the company operates across multiple Latin American markets, combining regional regulatory expertise with established capabilities in institutional promotion and distribution. www.lablibra.com

Advisors

Sathguru Management Consultants acted as exclusive advisor to Orchid Pharma on the transaction.

Registered Office:

Orchid Pharma Limited
Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate,
Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India.

Corporate Office:

15th Floor, Tower 1, DLF Corporate Greens, Sector 74A,
Gurugram - 122004, Haryana, India